Deferasirox and children: From clinical trials to the real world

Am J Hematol. 2016 Jun;91(6):E304-5. doi: 10.1002/ajh.24353. Epub 2016 Apr 13.

Authors

Raffaella Origa¹, Antonietta Zappu², Maria Loreta Foschini², Giovanbattista Leoni², Maddalena Morittu², Paolo Moi¹, Mara Corpino², Carlo Dessì²

Affiliations

¹ Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy.
² Ospedale Pediatrico Microcitemico "a.Cao"- a.O. G.Brotzu, Cagliari, Italy.

PMID: 26950047
DOI: 10.1002/ajh.24353

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Benzoates / administration & dosage
Benzoates / therapeutic use*
Child
Clinical Trials as Topic
Deferasirox
Humans
Iron Chelating Agents / administration & dosage
Iron Chelating Agents / therapeutic use*
Iron Overload / diagnosis
Iron Overload / drug therapy*
Iron Overload / etiology
Transfusion Reaction
Treatment Outcome
Triazoles / administration & dosage
Triazoles / therapeutic use*
beta-Thalassemia / complications
beta-Thalassemia / therapy

Substances

Benzoates
Iron Chelating Agents
Triazoles
Deferasirox